Dr Michael Friedlander

Honorary Associate
Medicine, Sydney Medical School
NHMRC Clinical Trials Centre


Map

Selected grants

2014

  • REZOLVE: A Phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant gynaecological cancers; Sjoquist K, Friedlander M, Quinn M, Bowtell D, Mileshkin L, Shannon C, Martyn J, Yip S; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • PARAGON: Phase II study of aromatase inhibitors in women with potentially hormone responsive recurrent/metastatic gynaecological neoplasms; Friedlander M, Sjoquist K, Beale P; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • Does Palliative Chemotherapy Palliate Measuring symptom benefit in recurrent ovarian cancer using patient reported outcomes: The Symptom Benefit Study; Friedlander M, King M, Oza A, Ledermann J, O'Connell R, Sjoquist K, Martyn J, Lee C; National Health and Medical Research Council (NHMRC)/Project Grants.

2013

  • A Phase II study to evaluate the safety and potential benefit of intraperitoneal (IP) bevacizumab to control symptomatic malignant ascites in patients with chemotherapy resistant ovarian cancers: REZOLVE (ANZGOG-1101); Friedlander M, Sjoquist K, Martyn J; Ovarian Cancer Research Foundation/Research Support.
  • Value of serum levels of Inhibin A, inhibin B, total inhibin and anti- Mullerian Hormone ( AMH) in measuring response of recurrent Granulosa cell tumours to Anastrazole; Friedlander M, Sjoquist K, Robertson D, BURGER H, Martyn J; Ovarian Cancer Research Foundation/Research Support.
  • ICON8: An international multi-stage randomised phase III trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy for women with newly diagnosed epithelial ovarian cancer; Friedlander M, Quinn M, Mileshkin L, Ledermann J, Clamp A, Dean A, Beale P, Sjoquist K, Martyn J; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The OUTBACK trial; Mileshkin L, Narayan K, Rischin D, Quinn M, Friedlander M, Moore K, Kitchener H, Shrivastava S, Martyn J, Small Jnr W; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Development and operational support for ANZGOG through the NHMRC Clinical Trials Centre: A NSW lead initiative.; Brand A, Friedlander M, Stockler M, Sjoquist K, Gebski V; Cancer Institute New South Wales/Cooperative Clinical Trial (CCT) Grants.

2011

  • A randomised, placebo-controlled trial of concurrent cediranib (AZD2171), with platinum-based chemotherapy and maintenance tcediranib in women with platinum-sensitive relapsed ovarian cancer: ICON 6; Friedlander M; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • Study to evaluate the safety and efficacy of intraperitoneal bevacizumab in patients with advanced platinum refractory or resistant ovarian cancer and symptomatic ascites; Friedlander M, Sjoquist K, Martyn J; DVC Research/Cancer Research Fund.
  • A novel approach to optimizing PARP inhibitor therapy in patients with triple negative and BRCA-associated breast cancer; Friedlander M, Wilcken N, Mitchell G; National Breast Cancer Foundation/Novel Concept Awards.

2010

  • Phase 2 study of aromatase inhibitors in women with potentially hormone sensitive recurrent metatastic gynaecological neoplasms:PARAGON; Friedlander M, Vaughan M, Quinn M, McCarthy N, Vaughan M, Harnett P, Gainford M; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • Breast cancer biospecimen resource; Morey A, Forbes J, Scott R, Spigelman A, Clarke C, Kefford R, Baxter R, Marsh D, Friedlander M, Harnett P, Balleine R, Bilous M, Boyages J, Sutherland R; National Health and Medical Research Council (NHMRC)/Enabling Grants.

2009

  • Development and operational support for AGITG and ANZGOG through the NHMRC Clinical Trials Centre: A NSW-led initiative; Simes R, Friedlander M, Goldstein D, Gainford M; Cancer Institute New South Wales/Clinical Trials Infrastructure Grants.
  • Biostatistics, quality assurance and data systems for cancer trial groups activities based at the NHMRC Clinical Trials Centre; Gebski V, Simes R, Hague W, Gainford M, Stockler M, Goldstein D, Friedlander M, Grimison P; Cancer Institute New South Wales/Clinical Trials Infrastructure Grants.
  • Does Palliative Chemotherapy Improve Symptoms in Women with Recurrent Ovarian Cancer; Friedlander M, King M, King M, Gainford M, Oza A, FitzGerald P; National Health and Medical Research Council (NHMRC)/Project Grants.

2008

  • Accelerated first line chemotherapy for advanced germ cell tumours; Friedlander M, Grimison P, Stockler M, Toner G; Cancer Council New South Wales/Research Project Grants.
  • Intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian cancer; Friedlander M, Gainford M; Cancer Council New South Wales/Research Project Grants.
  • ANZGOG - Australia New Zealand Gynaecological Oncology Group; Friedlander M; Cancer Australia/Support for Cancer Clinical Trials.

2007

  • Breast Cancer Tissue Bank; Marsh D, Clarke C, Scott R, Kefford R, Balleine R, Baxter R, Bilous M, Carpenter J, Friedlander M, Forbes J, Boyages J, Spigelman A, Sutherland R, Harnett P, Morey A; National Breast Cancer Foundation/Research Grants.

2006

  • Carboplatin flat dosing versus intrapatient dose escalation in first line chemotherapy of ovarian cancer; Friedlander M, Quinn M, Koczwara B, Quinn M, Vasey P; Cancer Council New South Wales/Research Project Grants.
  • OVERcome (Olive oil, Vaginal Exercise and Replens): An intervention study to improve sexual function in women with breast cancer; Friedlander M, Jarvis S, Meiser B, Juraskova I; Susan G. Komen Breast Cancer Foundation (USA)/Research Grant.
  • Strengthen Cancer Care initiative - Infrastructure Support for Clinical Trials Program; Friedlander M; Commonwealth Department of Health and Ageing/Strengthening Support For Cancer Care.

2005

  • The development and evaluation of a menopause information tool for young women following breast cancer; Meiser B, Friedlander M, Gregson J, De A, Hickey M, Waters M, Saunders C, White K, Thewes B; National Breast Cancer Foundation/Research Grant.
  • Breast cancer biospecimen resource; Marsh D, Clarke C, Harnett P, Spigelman A, Forbes J, Harnett P, Friedlander M, Sutherland R, Boyages J, Morey A, Spigelman A, Scott R, Balleine R, Baxter R, Bilous M, Kefford R; Cancer Institute New South Wales/Research Grant.
  • Breast Cancer biospecimen resource; Boyages J, Spigelman A, Forbes J, Marsh D, Friedlander M, Morey A, Spigelman A, Sutherland R, Scott R, Balleine R, Baxter R, Bilous M, Kefford R, Clarke C; National Breast Cancer Foundation/Grant-in-Aid.

2004

  • Breast cancer biospecimen resource; Clarke C, Balleine R, Bilous M, Kefford R, Baxter R, Harnett P, Spigelman A, Forbes J, Spigelman A, Marsh D, Boyages J, Friedlander M, Harnett P, Morey A, Scott R, Sutherland R; National Health and Medical Research Council (NHMRC)/Enabling Grants.

2002

  • A randomised trial of a decision aid for women at risk for ovarian cancer; Friedlander M; National Health and Medical Research Council (NHMRC)/Project Grants.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Grimison, P., Stockler, M., Chatfield, M., Thomson, D., Gebski, V., Friedlander, M., Boland, A., Houghton, B., Gruney, H., Rosenthal, M., et al (2014). Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Annals of Oncology, 25(1), 143-148. [More Information]
  • Butow, P., Price, M., Bell, M., Webb, P., deFazio, A., Friedlander, M. (2014). Caring for women with ovarian cancer in the last year of life: A longitudinal study of caregiver quality of life, distress and unmet needs. Gynecologic Oncology, 132(3), 690-697. [More Information]
  • King, M., Stockler, M., Butow, P., O'Connell, R., Voysey, M., Oza, A., Gillies, K., Donovan, H., Mercieca-Bebber, R., Martyn, J., Sjoquist, K., Friedlander, M. (2014). Development of the Measure of Ovarian Symptoms and Treatment Concerns: Aiming for Optimal Measurement of Patient-Reported Symptom Benefit with Chemotherapy for Symptomatic Ovarian Cancer. International Journal of Gynecological Cancer, 24(5), 865-873. [More Information]
  • Stockler, M., Hilpert, F., Friedlander, M., King, M., Wenzel, L., Lee, C., Joly, F., de Gregorio, N., Arranz, J., Mirza, M., et al (2014). Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer. Journal of Clinical Oncology, 32(13), 1309-1316. [More Information]
  • Friedlander, M., Stockler, M., O'Connell, R., Voysey, M., Oza, A., Gillies, K., Donovan, H., Martyn, J., Sjoquist, K., Butow, P., King, M., et al (2014). Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study. International Journal of Gynecological Cancer, 24(5), 857-864. [More Information]
  • Park, S., Goldstein, D., Krishnan, A., Lin, C., Friedlander, M., Cassidy, J., Koltzenburg, M., Kiernan, M. (2013). Chemotherapy-induced peripheral neurotoxicity: A critical analysis. CA: A Cancer Journal for Clinicians, 63(6), 419-437. [More Information]
  • Friedlander, M., Stockler, M., Butow, P., King, M., McAlpine, J., Tinker, A., Ledermann, J. (2013). Clinical Trials of Palliative Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: Time to Think Differently? Journal of Clinical Oncology, 31(18), 2362. [More Information]
  • Gleeson, M., Meiser, B., Barlow-Stewart, K., Trainer, A., Tucker, K., Watts, K., Friedlander, M., Kasparian, N. (2013). Communication and information needs of women diagnosed with ovarian cancer regarding treatment-focused genetic testing. Oncology Nursing Forum, 40(3), 275-283. [More Information]
  • Blinman, P., Gainford, C., Donoghoe, M., Martyn, J., Bloomfield, P., Grant, P., Kichenadasse, G., Vaughan, M., Brand, A., Shannon, C., Gebski, V., Stockler, M., et al (2013). Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study. Journal of Gynecologic Oncology, 24(4), 359-366. [More Information]
  • Sjoquist, K., Friedlander, M., O'Connell, R., Voysey, M., King, M., Stockler, M., Oza, A., Gillies, K., Martyn, J., Butow, P. (2013). Hope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecological Cancer Intergroup Symptom Benefit Study. The Oncologist, 18(11), 1221-1228. [More Information]
  • Sommeijer, D., Sjoquist, K., Friedlander, M. (2013). Hormonal Treatment in Recurrent and Metastatic Gynaecological Cancers: A Review of the Current Literature. Current Oncology Reports, 15(6), 541-548. [More Information]
  • Friedlander, M., King, M. (2013). Patient-reported outcomes in ovarian cancer clinical trials. Annals of Oncology, 24(Suppl 10), 64-68. [More Information]
  • Jordan, S., Steer, C., deFazio, A., Quinn, M., Obermair, A., Friedlander, M., Francis, J., O'Brien, S., Goss, G., Wyld, D., et al (2013). Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer - a population-based study. Gynecologic Oncology, 129(2), 310-317. [More Information]
  • Price, M., Bell, M., Sommeijer, D., Friedlander, M., Stockler, M., deFazio, A., Webb, P., Butow, P. (2013). Physical symptoms, coping styles and quality of life in recurrent ovarian cancer: A prospective population-based study over the last year of life. Gynecologic Oncology, 130(1), 162-168. [More Information]
  • Hacker, N., Barlow, E., Scurry, J., Gebski, V., Farrell, R., Robertson, G., Friedlander, M., Jackson, M. (2013). Primary surgical management with tailored adjuvant radiation for stage IB2 cervical cancer. Obstetrics & Gynecology, 121(4), 765-772. [More Information]
  • Thewes, B., Bell, M., Butow, P., Beith, J., Boyle, F., Friedlander, M., McLachlan, S. (2013). Psychological morbidity and stress but not social factors influence level of fear of cancer recurrence in young women with early breast cancer: results of a cross-sectional study. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 22(12), 2797-2806. [More Information]
  • Juraskova, I., Sherin, J., Mok, K., Peate, M., Meiser, B., Cheah, B., Mireskandari, S., Friedlander, M. (2013). The acceptability, feasibility, and efficacy (Phase I/II Study) of the OVERcome (Olive Oil, Vaginal Exercise, and MoisturizeR) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancer. Journal of Sexual Medicine, 10(10), 2549-2558. [More Information]
  • Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M., Webb, P., Stewart, C., et al (2012). BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology, 30(21), 2654-2663. [More Information]
  • Goldstein, D., Bennett, B., Webber, K., Boyle, F., De Souza, P., Wilcken, N., Scott, E., Toppler, R., Murie, P., O'Malley, L., Hickie, I., et al (2012). Cancer-Related Fatigue in Women With Breast Cancer: Outcomes of a 5-Year Prospective Cohort Study. Journal of Clinical Oncology, 30(15), 1805-1812. [More Information]
  • Watts, K., Meiser, B., Mitchell, G., Kirk, J., Saunders, C., Peate, M., Duffy, J., Kelly, P., Gleeson, M., Barlow-Stewart, K., et al (2012). How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer. BMC Cancer, 12(1), 1-12. [More Information]
  • Bennett, B., Park, S., Lin, C., Friedlander, M., Kiernan, M., Goldstein, D. (2012). Impact of oxaliplatin-induced neuropathy: a patient perspective. Supportive Care in Cancer, 20(11), 2959-2967. [More Information]
  • Peate, M., Meiser, B., Cheah, B., Saunders, C., Butow, P., Thewes, B., Hart, R., Phillips, K., Hickey, M., Friedlander, M. (2012). Making hard choices easier: A prospective, multicentre study to assess the efficacy of a fertility-related decision aid in young women with early-stage breast cancer. British Journal of Cancer, 106(6), 1053-1061. [More Information]
  • Cameron, B., Bennett, B., Li, H., Boyle, F., deSouza, P., Wilcken, N., Friedlander, M., Goldstein, D., Lloyd, A. (2012). Post-cancer fatigue is not associated with immune activation or altered cytokine production. Annals of Oncology, 23(11), 2890-2895. [More Information]
  • Lee, C., Hudson, M., Stockler, M., Coates, A., Ackland, S., Gebski, V., Lord, S., Friedlander, M., Boyle, F., Simes, R. (2011). A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer. Breast Cancer Research and Treatment, 129(2), 467-476. [More Information]
  • Kiely, B., Friedlander, M., Milne, R., Stanhope, L., Russell, P., Jenkins, M., Weideman, P., McLachlan, S., Grant, P., kConFab Investigators., et al (2011). Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer. Familial Cancer, 10(3), 505-514. [More Information]
  • Collins, I., Roberts-Thomson, R., Faulkner, D., Rischin, D., Friedlander, M., Mileshkin, L. (2011). Carboplatin Dosing in Ovarian Cancer: Problems and Pitfalls. International Journal Of Gynecological Cancer, 21(7), 1213-1218. [More Information]
  • Lee, C., Gurney, H., Brown, C., Sorio, R., Donadello, N., Tulunay, G., Meier, W., Bacon, M., Maenpaa, J., Petru, E., Gebski, V., Lord, S., Simes, R., et al (2011). Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. British Journal of Cancer, 105(3), 360-365. [More Information]
  • Friedlander, M., Trimble, E., Tinker, A., Alberts, D., Avall-Lundqvist, E., Brady, M., Harter, P., Pignata, S., Pujade- Lauraine, E., Sehouli, J., Beale, P., et al (2011). Clinical Trials in Recurrent Ovarian Cancer. International Journal Of Gynecological Cancer, 21(4), 771-775. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2011). Dose effects of oxaliplatin on persistent and transient na conductances and the development of neurotoxicity. PloS One, 6(4), e18469-e18469. [More Information]
  • Lee, C., Friedlander, M., Brown, C., Gebski, V., Georgoulopoulos, A., Vergote, I., Pignata, S., Donadello, N., Schmalfeldt, B., Delva, R., Lord, S., Simes, R., et al (2011). Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer. Journal of the National Cancer Institute, 103(17), 1338-1342. [More Information]
  • Park, S., Lin, C., Krishnan, A., Friedlander, M., Lewis, C., Kiernan, M. (2011). Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. Muscle and Nerve, 43(3), 367-674. [More Information]
  • Webber, K., Mok, K., Bennett, B., Lloyd, A., Friedlander, M., Juraskova, I., Goldstein, D. (2011). If I Am in the Mood, I Enjoy It: An Exploration of Cancer-Related Fatigue and Sexual Functioning in Women with Breast Cancer. The Oncologist, 16, 1333-1344. [More Information]
  • Anglesio, M., George, J., Kulbe, H., Friedlander, M., Rischin, D., Lemech, C., Power, J., Coward, J., Cowin, P., House, C., deFazio, A., et al (2011). IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer. Clinical Cancer Research, 17(8), 2538-2548. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2011). Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility. The Oncologist, 16(5), 708-716. [More Information]
  • Park, S., Goldstein, D., Lin, C., Krishnan, A., Friedlander, M., Kiernan, M. (2011). Neuroprotection for Oxaliplatin-Induced Neurotoxicity: What Happened to Objective Assessment? Journal of Clinical Oncology, 29(18), e553-e554. [More Information]
  • Lee, C., Simes, R., Brown, C., Lord, S., Wagner, U., Plante, M., Vergote, I., Pisano, C., Parma, G., Burges, A., Gebski, V., et al (2011). Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. British Journal of Cancer, 105(8), 1144-1150. [More Information]
  • Sjoquist, K., Martyn, J., Edmondson, R., Friedlander, M. (2011). The role of hormonal therapy in gynecological cancers-current status and future directions. International Journal Of Gynecological Cancer, 21(7), 1328-1333. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2011). Utilising natural activity to dissect the Pathophysiology of acute oxaliplatin-induced neuropathy. Experimental Neurology, 227(1), 120-127. [More Information]
  • Luckett, T., King, M., Butow, P., Friedlander, M., Paris, T. (2010). Assessing Health-Related Quality of Life in Gynecologic Oncology: A Systematic Review of Questionnaires and Their Ability to Detect Clinically Important Differences and Change. International Journal Of Gynecological Cancer, 20(4), 664-684. [More Information]
  • Kiely, B., Jenkins, M., McKinley, J., Friedlander, M., Weideman, P., Milne, R., McLachlan, S., Hopper, J., Phillips, K. (2010). Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab). Breast Cancer Research and Treatment, 120(3), 715-723. [More Information]
  • Gainford, M., Tinker, A., Carter, J., Petru, E., Nicklin, J., Quinn, M., Hammond, I., Elit, L., Lenhard, M., Friedlander, M. (2010). Malignant transformation within ovarian dermoid cysts: an audit of treatment received and patient outcomes. an australia new zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIG) study. International Journal of Gynecological Cancer, 20(1), 75-81. [More Information]
  • Park, S., Goldstein, D., Lin, C., Krishnan, A., Friedlander, M., Kiernan, M. (2009). Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. Journal of Clinical Oncology, 27(8), 1243-1249. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2009). Oxaliplatin-Induced Lhermitte's Phenomenon as a Manifestation of Severe Generalized Neurotoxicity. Neuro-Oncology, 77(6), 342-348. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2009). Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain: a journal of neurology, 132(10), 2712-2723. [More Information]
  • Field, K., Jenkins, M., Friedlander, M., McKinley, J., Price, M., Weideman, P., Keogh, L., McLachlan, S., Lindeman, G., Hopper, J., Butow, P., et al (2009). Predictors of the use of Complementary and Alternative Medicine (CAM) by women at high risk for breast cancer. European Journal of Cancer, 45(4), 551-560. [More Information]
  • Price, M., Zachariae, R., Butow, P., deFazio, A., Patel (nee Chauhan), D., Espie, C., Friedlander, M., Webb, P. (2009). Prevalence and predictors of insomnia in women with invasive ovarian cancer: Anxiety a major factor. European Journal of Cancer, 45(18), 3262-3270. [More Information]
  • Friedlander, M., Butow, P., Stockler, M., Gainford, C., Martyn, J., Oza, A., Donovan, H., Miller, B., King, M. (2009). Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer. International Journal Of Gynecological Cancer, 19(Suppl 2), S44-S48. [More Information]
  • Dawson, S., Price, M., Jenkins, M., McKinley, J., Butow, P., McLachlan, S., Lindeman, G., Weideman, P., Friedlander, M., Hopper, J., et al (2008). Cancer risk management practices of noncarriers within BRCA1/2 mutation - Positive families in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast cancer. Journal of Clinical Oncology, 26(2), 225-232.
  • Meiser, B., Tucker, K., Friedlander, M., Barlow-Stewart, K., Lobb, E., Saunders, C., Mitchell, G. (2008). Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda. Breast Cancer Research, 10(6), 216. [More Information]
  • Mok, K., Juraskova, I., Friedlander, M. (2008). The impact of aromatase inhibitors on sexual functioning: Current knowledge and future research directions. The Breast Journal, 17, 436-440. [More Information]
  • Clarke, S., Goldstein, D., Mitchell, P., Michael, M., Beale, P., Friedlander, M., Zalcberg, J., White, S. (2007). Modification of Leucovorin Dose Within a Simplified FOLFOX Regimen Improves Tolerability Without Compromising Efficacy. Clinical Colorectal Cancer, 6(8), 578-582. [More Information]
  • Friedlander, M., Buck, M., Wyld, D., Findlay, M., Fitzharris, B., De Souza, P., Davies, T., Kalimi, G., Allan, S., Perez, D., Harnett, P. (2007). Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer. International Journal Of Gynecological Cancer, 17(2), 350-358. [More Information]
  • Bennett, B., Goldstein, D., Friedlander, M., Hickie, I., Lloyd, A. (2007). The experience of cancer related fatigue and chronic fatigue syndrome: A qualitative and comparative study. Journal of Pain and Symptom Management, 34(2), 126-135. [More Information]
  • Bennett, B., Goldstein, D., Friedlander, M., Hickie, I., Lloyd, A. (2007). The Experience of Cancer-Related Fatigue and Chronic Fatigue Syndrome: A Qualitative and Comparative Study. Journal of Pain and Symptom Management, 34(2), 126-135. [More Information]
  • Tiller, K., Meiser, B., Gaff, C., Kirk, J., Dudding, T., Phillips, K., Friedlander, M., Tucker, K. (2006). A randomized controlled trial of a decision aid for women at increased risk of ovarian cancer. Medical Decision Making: an international journal, 26(4), 360-372. [More Information]
  • Mitchell, P., Goldstein, D., Michael, M., Beale, P., Friedlander, M., Zalcberg, J., White, S., Thomson, J., Clarke, S. (2006). Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clinical Colorectal Cancer, 6(2), 146-151. [More Information]
  • Aghmesheh, M., Suo, Z., Friedlander, M., Nesland, J., Kaern, J., Stewart, M., Dorum, A., Tucker, K., Buckley, M. (2006). Chromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomas. Pathology, 38(2), 145-151.
  • Goldstein, D., Bennett, B., Friedlander, M., Davenport, T., Hickie, I., Lloyd, A. (2006). Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study. BMC Cancer, 6, 1-8. [More Information]
  • Michael, M., Goldstein, D., Clarke, S., Milner, A., Beale, P., Friedlander, M., Mitchell, P. (2006). Prognostic Factors Predictive of Response and Survival to a Modified FOLFOX Regimen: Importance of an Increased Neutrophil Count. Clinical Colorectal Cancer, 6(4), 297-304.
  • Mitchell, P., Goldstein, D., Michael, M., Beale, P., Friedlander, M., Zalcberg, J., White, S., Clarke, S. (2005). Addition of gabapentin (G) to a modified FOLFOX regimen does not reduce neurotoxicity in patients (pts) with advanced colorectal cancer (CRC). Journal of Clinical Oncology, 23(No 16S (June 1 Supplement)), 3581-3581.
  • Goldstein, D., Mitchell, P., Michael, M., Beale, P., Friedlander, M., Zalcberg, J., White, S., Clarke, S. (2005). Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients. British Journal of Cancer, 92(5), 832-837. [More Information]
  • Aghmesheh, M., Edwards, L., Clarke, C., Byth Wilson, K., Katzenellenbogen, B., Russell, P., Friedlander, M., Tucker, K., deFazio, A. (2005). Expression of steroid hormone receptors in BRCA1-associated ovarian carcinomas. Gynecologic Oncology, 97(1), 16-25. [More Information]
  • Thewes, B., Meiser, B., Taylor, A., Phillips, K., Pendlebury, S., Capp, A., Dalley, D., Goldstein, D., Baber, R., Friedlander, M. (2005). Fertility- and menopause-related information needs of younger women with a diagnosis of early breast cancer. Journal of Clinical Oncology, 23(22), 5155-5165. [More Information]
  • Phillips, K., Butow, P., Stewart, A., Chang, J., Weideman, P., Price, M., McLachlan, S., Lindeman, G., McKay, M., Friedlander, M., et al (2005). Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort. Familial Cancer, 4(2), 105-113. [More Information]
  • Thewes, B., Meiser, B., Duric, V., Stockler, M., Taylor, A., Stuart-Harris, R., Links, M., Wilcken, N., McLachlan, S., Phillips, K., Boyle, F., et al (2005). What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? Lancet Oncology, 6(8), 581-588. [More Information]
  • Rischin, D., Phillips, K., Friedlander, M., Harnett, P., Quinn, M., Richardson, G., Martin, A. (2004). A Phase II Trial Of Capecitabine In Heavily Pre-Treated Platinum-Resistant Ovarian Cancer. Gynecologic Oncology, 93(2), 417-421.
  • Aghmesheh, M., Nesland, J., Kaern, J., Dorum, A., Edwards, L., Byth Wilson, K., Friedlander, M., Jackson, P., Tucker, K., Russell, P. (2004). No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers. Gynecologic Oncology, 95(3), 430-436.
  • Tiller, K., Meiser, B., Reeson, E., Tucker, M., Andrews, L., Gaff, C., Kirk, J., Phillips, K., Friedlander, M. (2003). A decision aid for women at increased risk for ovarian cancer. International Journal Of Gynecological Cancer, 13(1), 15-22.
  • Friedlander, M., Thewes, B. (2003). Counting the costs of treatment: the reproductive and gynaecological consequences of adjuvant therapy in young women with breast cancer. Internal Medicine Journal, 33(8), 372-379.
  • Meiser, B., Butow, P., Friedlander, M., Barratt, A., Schnieden, V., Watson, M., Brown, J., Tucker, K. (2002). Psychological impact of genetic testing in women from high-risk breast cancer families. European Journal of Cancer, 38(15), 2025-2031.
  • Tiller, K., Meiser, B., Butow, P., Clifton, M., Thewes, B., Friedlander, M., Tucker, K. (2002). Psychological impact of prophylactic oophorectomy in women at increased risk of developing ovarian cancer: a prospective study. Gynecologic Oncology, 86(2), 212-219. [More Information]
  • Pribill, I., Speiser, P., Leary, J., Leodolter, S., Hacker, N., Friedlander, M., Birnbaum, D., Zeillinger, R., Krainer, M. (2001). High frequency of allelic imbalance at regions of chromosome arm 8p in ovarian carcinoma. Cancer Genetics and Cytogenetics, 129(1), 23-29.
  • Leary, J., Friedlander, M. (2001). The molecular genetics of epithelial ovarian cancer. Gynaecological Oncology, 2(4), 85-91.
  • Meiser, B., Butow, P., Barratt, A., Friedlander, M., Kirk, J., Gaff, C., Haan, E., Aittomaki, K., Tucker, K. (2000). Breast cancer screening uptake in women at increased risk of developing hereditary breast cancer. Breast Cancer Research and Treatment, 59(2), 101-111.
  • Meiser, B., Butow, P., Friedlander, M., Schnieden, V., Gattas, M., Kirk, J., Suthers, G., Haan, E., Tucker, K. (2000). Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer. Journal of Clinical Oncology, 18(11), 2250-2257.

Conferences

  • Kiely, B., Jenkins, M., McKinley, J., Friedlander, M., Weideman, P., Milne, R., McLachlan, S., Hopper, J., Phillips, K. (2009). Contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab). 2009 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • Kiely, B., Phillips, K., Burnham, L., Russell, P., Jenkins, M., Weideman, P., Hopper, J., McLachlan, S., Friedlander, M. (2009). Prospective Study of Adequacy of Risk-Reducing Salpingo-Oophorectomy in Australasian BRCA1/2 Carriers in Women at High Familial Risk of Ovarian Cancer in the Kathleen Cunningham Foundation Consortium For Research Into Familial Breast Cancer (kConFab). Clinical Oncological Society of Australia (COSA) 36th Annual Scientific Meeting, Gold Coast, Australia: Wiley-Blackwell Publishing Asia Pty Ltd.

2014

  • Grimison, P., Stockler, M., Chatfield, M., Thomson, D., Gebski, V., Friedlander, M., Boland, A., Houghton, B., Gruney, H., Rosenthal, M., et al (2014). Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Annals of Oncology, 25(1), 143-148. [More Information]
  • Butow, P., Price, M., Bell, M., Webb, P., deFazio, A., Friedlander, M. (2014). Caring for women with ovarian cancer in the last year of life: A longitudinal study of caregiver quality of life, distress and unmet needs. Gynecologic Oncology, 132(3), 690-697. [More Information]
  • King, M., Stockler, M., Butow, P., O'Connell, R., Voysey, M., Oza, A., Gillies, K., Donovan, H., Mercieca-Bebber, R., Martyn, J., Sjoquist, K., Friedlander, M. (2014). Development of the Measure of Ovarian Symptoms and Treatment Concerns: Aiming for Optimal Measurement of Patient-Reported Symptom Benefit with Chemotherapy for Symptomatic Ovarian Cancer. International Journal of Gynecological Cancer, 24(5), 865-873. [More Information]
  • Stockler, M., Hilpert, F., Friedlander, M., King, M., Wenzel, L., Lee, C., Joly, F., de Gregorio, N., Arranz, J., Mirza, M., et al (2014). Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer. Journal of Clinical Oncology, 32(13), 1309-1316. [More Information]
  • Friedlander, M., Stockler, M., O'Connell, R., Voysey, M., Oza, A., Gillies, K., Donovan, H., Martyn, J., Sjoquist, K., Butow, P., King, M., et al (2014). Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study. International Journal of Gynecological Cancer, 24(5), 857-864. [More Information]

2013

  • Park, S., Goldstein, D., Krishnan, A., Lin, C., Friedlander, M., Cassidy, J., Koltzenburg, M., Kiernan, M. (2013). Chemotherapy-induced peripheral neurotoxicity: A critical analysis. CA: A Cancer Journal for Clinicians, 63(6), 419-437. [More Information]
  • Friedlander, M., Stockler, M., Butow, P., King, M., McAlpine, J., Tinker, A., Ledermann, J. (2013). Clinical Trials of Palliative Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: Time to Think Differently? Journal of Clinical Oncology, 31(18), 2362. [More Information]
  • Gleeson, M., Meiser, B., Barlow-Stewart, K., Trainer, A., Tucker, K., Watts, K., Friedlander, M., Kasparian, N. (2013). Communication and information needs of women diagnosed with ovarian cancer regarding treatment-focused genetic testing. Oncology Nursing Forum, 40(3), 275-283. [More Information]
  • Blinman, P., Gainford, C., Donoghoe, M., Martyn, J., Bloomfield, P., Grant, P., Kichenadasse, G., Vaughan, M., Brand, A., Shannon, C., Gebski, V., Stockler, M., et al (2013). Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study. Journal of Gynecologic Oncology, 24(4), 359-366. [More Information]
  • Sjoquist, K., Friedlander, M., O'Connell, R., Voysey, M., King, M., Stockler, M., Oza, A., Gillies, K., Martyn, J., Butow, P. (2013). Hope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecological Cancer Intergroup Symptom Benefit Study. The Oncologist, 18(11), 1221-1228. [More Information]
  • Sommeijer, D., Sjoquist, K., Friedlander, M. (2013). Hormonal Treatment in Recurrent and Metastatic Gynaecological Cancers: A Review of the Current Literature. Current Oncology Reports, 15(6), 541-548. [More Information]
  • Friedlander, M., King, M. (2013). Patient-reported outcomes in ovarian cancer clinical trials. Annals of Oncology, 24(Suppl 10), 64-68. [More Information]
  • Jordan, S., Steer, C., deFazio, A., Quinn, M., Obermair, A., Friedlander, M., Francis, J., O'Brien, S., Goss, G., Wyld, D., et al (2013). Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer - a population-based study. Gynecologic Oncology, 129(2), 310-317. [More Information]
  • Price, M., Bell, M., Sommeijer, D., Friedlander, M., Stockler, M., deFazio, A., Webb, P., Butow, P. (2013). Physical symptoms, coping styles and quality of life in recurrent ovarian cancer: A prospective population-based study over the last year of life. Gynecologic Oncology, 130(1), 162-168. [More Information]
  • Hacker, N., Barlow, E., Scurry, J., Gebski, V., Farrell, R., Robertson, G., Friedlander, M., Jackson, M. (2013). Primary surgical management with tailored adjuvant radiation for stage IB2 cervical cancer. Obstetrics & Gynecology, 121(4), 765-772. [More Information]
  • Thewes, B., Bell, M., Butow, P., Beith, J., Boyle, F., Friedlander, M., McLachlan, S. (2013). Psychological morbidity and stress but not social factors influence level of fear of cancer recurrence in young women with early breast cancer: results of a cross-sectional study. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer, 22(12), 2797-2806. [More Information]
  • Juraskova, I., Sherin, J., Mok, K., Peate, M., Meiser, B., Cheah, B., Mireskandari, S., Friedlander, M. (2013). The acceptability, feasibility, and efficacy (Phase I/II Study) of the OVERcome (Olive Oil, Vaginal Exercise, and MoisturizeR) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancer. Journal of Sexual Medicine, 10(10), 2549-2558. [More Information]

2012

  • Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M., Webb, P., Stewart, C., et al (2012). BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology, 30(21), 2654-2663. [More Information]
  • Goldstein, D., Bennett, B., Webber, K., Boyle, F., De Souza, P., Wilcken, N., Scott, E., Toppler, R., Murie, P., O'Malley, L., Hickie, I., et al (2012). Cancer-Related Fatigue in Women With Breast Cancer: Outcomes of a 5-Year Prospective Cohort Study. Journal of Clinical Oncology, 30(15), 1805-1812. [More Information]
  • Watts, K., Meiser, B., Mitchell, G., Kirk, J., Saunders, C., Peate, M., Duffy, J., Kelly, P., Gleeson, M., Barlow-Stewart, K., et al (2012). How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer. BMC Cancer, 12(1), 1-12. [More Information]
  • Bennett, B., Park, S., Lin, C., Friedlander, M., Kiernan, M., Goldstein, D. (2012). Impact of oxaliplatin-induced neuropathy: a patient perspective. Supportive Care in Cancer, 20(11), 2959-2967. [More Information]
  • Peate, M., Meiser, B., Cheah, B., Saunders, C., Butow, P., Thewes, B., Hart, R., Phillips, K., Hickey, M., Friedlander, M. (2012). Making hard choices easier: A prospective, multicentre study to assess the efficacy of a fertility-related decision aid in young women with early-stage breast cancer. British Journal of Cancer, 106(6), 1053-1061. [More Information]
  • Cameron, B., Bennett, B., Li, H., Boyle, F., deSouza, P., Wilcken, N., Friedlander, M., Goldstein, D., Lloyd, A. (2012). Post-cancer fatigue is not associated with immune activation or altered cytokine production. Annals of Oncology, 23(11), 2890-2895. [More Information]

2011

  • Lee, C., Hudson, M., Stockler, M., Coates, A., Ackland, S., Gebski, V., Lord, S., Friedlander, M., Boyle, F., Simes, R. (2011). A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer. Breast Cancer Research and Treatment, 129(2), 467-476. [More Information]
  • Kiely, B., Friedlander, M., Milne, R., Stanhope, L., Russell, P., Jenkins, M., Weideman, P., McLachlan, S., Grant, P., kConFab Investigators., et al (2011). Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer. Familial Cancer, 10(3), 505-514. [More Information]
  • Collins, I., Roberts-Thomson, R., Faulkner, D., Rischin, D., Friedlander, M., Mileshkin, L. (2011). Carboplatin Dosing in Ovarian Cancer: Problems and Pitfalls. International Journal Of Gynecological Cancer, 21(7), 1213-1218. [More Information]
  • Lee, C., Gurney, H., Brown, C., Sorio, R., Donadello, N., Tulunay, G., Meier, W., Bacon, M., Maenpaa, J., Petru, E., Gebski, V., Lord, S., Simes, R., et al (2011). Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. British Journal of Cancer, 105(3), 360-365. [More Information]
  • Friedlander, M., Trimble, E., Tinker, A., Alberts, D., Avall-Lundqvist, E., Brady, M., Harter, P., Pignata, S., Pujade- Lauraine, E., Sehouli, J., Beale, P., et al (2011). Clinical Trials in Recurrent Ovarian Cancer. International Journal Of Gynecological Cancer, 21(4), 771-775. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2011). Dose effects of oxaliplatin on persistent and transient na conductances and the development of neurotoxicity. PloS One, 6(4), e18469-e18469. [More Information]
  • Lee, C., Friedlander, M., Brown, C., Gebski, V., Georgoulopoulos, A., Vergote, I., Pignata, S., Donadello, N., Schmalfeldt, B., Delva, R., Lord, S., Simes, R., et al (2011). Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer. Journal of the National Cancer Institute, 103(17), 1338-1342. [More Information]
  • Park, S., Lin, C., Krishnan, A., Friedlander, M., Lewis, C., Kiernan, M. (2011). Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxel-induced neuropathy. Muscle and Nerve, 43(3), 367-674. [More Information]
  • Webber, K., Mok, K., Bennett, B., Lloyd, A., Friedlander, M., Juraskova, I., Goldstein, D. (2011). If I Am in the Mood, I Enjoy It: An Exploration of Cancer-Related Fatigue and Sexual Functioning in Women with Breast Cancer. The Oncologist, 16, 1333-1344. [More Information]
  • Anglesio, M., George, J., Kulbe, H., Friedlander, M., Rischin, D., Lemech, C., Power, J., Coward, J., Cowin, P., House, C., deFazio, A., et al (2011). IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer. Clinical Cancer Research, 17(8), 2538-2548. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2011). Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility. The Oncologist, 16(5), 708-716. [More Information]
  • Park, S., Goldstein, D., Lin, C., Krishnan, A., Friedlander, M., Kiernan, M. (2011). Neuroprotection for Oxaliplatin-Induced Neurotoxicity: What Happened to Objective Assessment? Journal of Clinical Oncology, 29(18), e553-e554. [More Information]
  • Lee, C., Simes, R., Brown, C., Lord, S., Wagner, U., Plante, M., Vergote, I., Pisano, C., Parma, G., Burges, A., Gebski, V., et al (2011). Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. British Journal of Cancer, 105(8), 1144-1150. [More Information]
  • Sjoquist, K., Martyn, J., Edmondson, R., Friedlander, M. (2011). The role of hormonal therapy in gynecological cancers-current status and future directions. International Journal Of Gynecological Cancer, 21(7), 1328-1333. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2011). Utilising natural activity to dissect the Pathophysiology of acute oxaliplatin-induced neuropathy. Experimental Neurology, 227(1), 120-127. [More Information]

2010

  • Luckett, T., King, M., Butow, P., Friedlander, M., Paris, T. (2010). Assessing Health-Related Quality of Life in Gynecologic Oncology: A Systematic Review of Questionnaires and Their Ability to Detect Clinically Important Differences and Change. International Journal Of Gynecological Cancer, 20(4), 664-684. [More Information]
  • Kiely, B., Jenkins, M., McKinley, J., Friedlander, M., Weideman, P., Milne, R., McLachlan, S., Hopper, J., Phillips, K. (2010). Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab). Breast Cancer Research and Treatment, 120(3), 715-723. [More Information]
  • Gainford, M., Tinker, A., Carter, J., Petru, E., Nicklin, J., Quinn, M., Hammond, I., Elit, L., Lenhard, M., Friedlander, M. (2010). Malignant transformation within ovarian dermoid cysts: an audit of treatment received and patient outcomes. an australia new zealand gynaecological oncology group (ANZGOG) and gynaecologic cancer intergroup (GCIG) study. International Journal of Gynecological Cancer, 20(1), 75-81. [More Information]

2009

  • Park, S., Goldstein, D., Lin, C., Krishnan, A., Friedlander, M., Kiernan, M. (2009). Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. Journal of Clinical Oncology, 27(8), 1243-1249. [More Information]
  • Kiely, B., Jenkins, M., McKinley, J., Friedlander, M., Weideman, P., Milne, R., McLachlan, S., Hopper, J., Phillips, K. (2009). Contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab). 2009 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2009). Oxaliplatin-Induced Lhermitte's Phenomenon as a Manifestation of Severe Generalized Neurotoxicity. Neuro-Oncology, 77(6), 342-348. [More Information]
  • Park, S., Lin, C., Krishnan, A., Goldstein, D., Friedlander, M., Kiernan, M. (2009). Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain: a journal of neurology, 132(10), 2712-2723. [More Information]
  • Field, K., Jenkins, M., Friedlander, M., McKinley, J., Price, M., Weideman, P., Keogh, L., McLachlan, S., Lindeman, G., Hopper, J., Butow, P., et al (2009). Predictors of the use of Complementary and Alternative Medicine (CAM) by women at high risk for breast cancer. European Journal of Cancer, 45(4), 551-560. [More Information]
  • Price, M., Zachariae, R., Butow, P., deFazio, A., Patel (nee Chauhan), D., Espie, C., Friedlander, M., Webb, P. (2009). Prevalence and predictors of insomnia in women with invasive ovarian cancer: Anxiety a major factor. European Journal of Cancer, 45(18), 3262-3270. [More Information]
  • Kiely, B., Phillips, K., Burnham, L., Russell, P., Jenkins, M., Weideman, P., Hopper, J., McLachlan, S., Friedlander, M. (2009). Prospective Study of Adequacy of Risk-Reducing Salpingo-Oophorectomy in Australasian BRCA1/2 Carriers in Women at High Familial Risk of Ovarian Cancer in the Kathleen Cunningham Foundation Consortium For Research Into Familial Breast Cancer (kConFab). Clinical Oncological Society of Australia (COSA) 36th Annual Scientific Meeting, Gold Coast, Australia: Wiley-Blackwell Publishing Asia Pty Ltd.
  • Friedlander, M., Butow, P., Stockler, M., Gainford, C., Martyn, J., Oza, A., Donovan, H., Miller, B., King, M. (2009). Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer. International Journal Of Gynecological Cancer, 19(Suppl 2), S44-S48. [More Information]

2008

  • Dawson, S., Price, M., Jenkins, M., McKinley, J., Butow, P., McLachlan, S., Lindeman, G., Weideman, P., Friedlander, M., Hopper, J., et al (2008). Cancer risk management practices of noncarriers within BRCA1/2 mutation - Positive families in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast cancer. Journal of Clinical Oncology, 26(2), 225-232.
  • Meiser, B., Tucker, K., Friedlander, M., Barlow-Stewart, K., Lobb, E., Saunders, C., Mitchell, G. (2008). Genetic counselling and testing for inherited gene mutations in newly diagnosed patients with breast cancer: a review of the existing literature and a proposed research agenda. Breast Cancer Research, 10(6), 216. [More Information]
  • Mok, K., Juraskova, I., Friedlander, M. (2008). The impact of aromatase inhibitors on sexual functioning: Current knowledge and future research directions. The Breast Journal, 17, 436-440. [More Information]

2007

  • Clarke, S., Goldstein, D., Mitchell, P., Michael, M., Beale, P., Friedlander, M., Zalcberg, J., White, S. (2007). Modification of Leucovorin Dose Within a Simplified FOLFOX Regimen Improves Tolerability Without Compromising Efficacy. Clinical Colorectal Cancer, 6(8), 578-582. [More Information]
  • Friedlander, M., Buck, M., Wyld, D., Findlay, M., Fitzharris, B., De Souza, P., Davies, T., Kalimi, G., Allan, S., Perez, D., Harnett, P. (2007). Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer. International Journal Of Gynecological Cancer, 17(2), 350-358. [More Information]
  • Bennett, B., Goldstein, D., Friedlander, M., Hickie, I., Lloyd, A. (2007). The experience of cancer related fatigue and chronic fatigue syndrome: A qualitative and comparative study. Journal of Pain and Symptom Management, 34(2), 126-135. [More Information]
  • Bennett, B., Goldstein, D., Friedlander, M., Hickie, I., Lloyd, A. (2007). The Experience of Cancer-Related Fatigue and Chronic Fatigue Syndrome: A Qualitative and Comparative Study. Journal of Pain and Symptom Management, 34(2), 126-135. [More Information]

2006

  • Tiller, K., Meiser, B., Gaff, C., Kirk, J., Dudding, T., Phillips, K., Friedlander, M., Tucker, K. (2006). A randomized controlled trial of a decision aid for women at increased risk of ovarian cancer. Medical Decision Making: an international journal, 26(4), 360-372. [More Information]
  • Mitchell, P., Goldstein, D., Michael, M., Beale, P., Friedlander, M., Zalcberg, J., White, S., Thomson, J., Clarke, S. (2006). Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clinical Colorectal Cancer, 6(2), 146-151. [More Information]
  • Aghmesheh, M., Suo, Z., Friedlander, M., Nesland, J., Kaern, J., Stewart, M., Dorum, A., Tucker, K., Buckley, M. (2006). Chromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomas. Pathology, 38(2), 145-151.
  • Goldstein, D., Bennett, B., Friedlander, M., Davenport, T., Hickie, I., Lloyd, A. (2006). Fatigue states after cancer treatment occur both in association with, and independent of, mood disorder: a longitudinal study. BMC Cancer, 6, 1-8. [More Information]
  • Michael, M., Goldstein, D., Clarke, S., Milner, A., Beale, P., Friedlander, M., Mitchell, P. (2006). Prognostic Factors Predictive of Response and Survival to a Modified FOLFOX Regimen: Importance of an Increased Neutrophil Count. Clinical Colorectal Cancer, 6(4), 297-304.

2005

  • Mitchell, P., Goldstein, D., Michael, M., Beale, P., Friedlander, M., Zalcberg, J., White, S., Clarke, S. (2005). Addition of gabapentin (G) to a modified FOLFOX regimen does not reduce neurotoxicity in patients (pts) with advanced colorectal cancer (CRC). Journal of Clinical Oncology, 23(No 16S (June 1 Supplement)), 3581-3581.
  • Goldstein, D., Mitchell, P., Michael, M., Beale, P., Friedlander, M., Zalcberg, J., White, S., Clarke, S. (2005). Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients. British Journal of Cancer, 92(5), 832-837. [More Information]
  • Aghmesheh, M., Edwards, L., Clarke, C., Byth Wilson, K., Katzenellenbogen, B., Russell, P., Friedlander, M., Tucker, K., deFazio, A. (2005). Expression of steroid hormone receptors in BRCA1-associated ovarian carcinomas. Gynecologic Oncology, 97(1), 16-25. [More Information]
  • Thewes, B., Meiser, B., Taylor, A., Phillips, K., Pendlebury, S., Capp, A., Dalley, D., Goldstein, D., Baber, R., Friedlander, M. (2005). Fertility- and menopause-related information needs of younger women with a diagnosis of early breast cancer. Journal of Clinical Oncology, 23(22), 5155-5165. [More Information]
  • Phillips, K., Butow, P., Stewart, A., Chang, J., Weideman, P., Price, M., McLachlan, S., Lindeman, G., McKay, M., Friedlander, M., et al (2005). Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort. Familial Cancer, 4(2), 105-113. [More Information]
  • Thewes, B., Meiser, B., Duric, V., Stockler, M., Taylor, A., Stuart-Harris, R., Links, M., Wilcken, N., McLachlan, S., Phillips, K., Boyle, F., et al (2005). What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? Lancet Oncology, 6(8), 581-588. [More Information]

2004

  • Rischin, D., Phillips, K., Friedlander, M., Harnett, P., Quinn, M., Richardson, G., Martin, A. (2004). A Phase II Trial Of Capecitabine In Heavily Pre-Treated Platinum-Resistant Ovarian Cancer. Gynecologic Oncology, 93(2), 417-421.
  • Aghmesheh, M., Nesland, J., Kaern, J., Dorum, A., Edwards, L., Byth Wilson, K., Friedlander, M., Jackson, P., Tucker, K., Russell, P. (2004). No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers. Gynecologic Oncology, 95(3), 430-436.

2003

  • Tiller, K., Meiser, B., Reeson, E., Tucker, M., Andrews, L., Gaff, C., Kirk, J., Phillips, K., Friedlander, M. (2003). A decision aid for women at increased risk for ovarian cancer. International Journal Of Gynecological Cancer, 13(1), 15-22.
  • Friedlander, M., Thewes, B. (2003). Counting the costs of treatment: the reproductive and gynaecological consequences of adjuvant therapy in young women with breast cancer. Internal Medicine Journal, 33(8), 372-379.

2002

  • Meiser, B., Butow, P., Friedlander, M., Barratt, A., Schnieden, V., Watson, M., Brown, J., Tucker, K. (2002). Psychological impact of genetic testing in women from high-risk breast cancer families. European Journal of Cancer, 38(15), 2025-2031.
  • Tiller, K., Meiser, B., Butow, P., Clifton, M., Thewes, B., Friedlander, M., Tucker, K. (2002). Psychological impact of prophylactic oophorectomy in women at increased risk of developing ovarian cancer: a prospective study. Gynecologic Oncology, 86(2), 212-219. [More Information]

2001

  • Pribill, I., Speiser, P., Leary, J., Leodolter, S., Hacker, N., Friedlander, M., Birnbaum, D., Zeillinger, R., Krainer, M. (2001). High frequency of allelic imbalance at regions of chromosome arm 8p in ovarian carcinoma. Cancer Genetics and Cytogenetics, 129(1), 23-29.
  • Leary, J., Friedlander, M. (2001). The molecular genetics of epithelial ovarian cancer. Gynaecological Oncology, 2(4), 85-91.

2000

  • Meiser, B., Butow, P., Barratt, A., Friedlander, M., Kirk, J., Gaff, C., Haan, E., Aittomaki, K., Tucker, K. (2000). Breast cancer screening uptake in women at increased risk of developing hereditary breast cancer. Breast Cancer Research and Treatment, 59(2), 101-111.
  • Meiser, B., Butow, P., Friedlander, M., Schnieden, V., Gattas, M., Kirk, J., Suthers, G., Haan, E., Tucker, K. (2000). Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer. Journal of Clinical Oncology, 18(11), 2250-2257.

To update your profile click here. For support on your academic profile contact .